The Precision Interventions for Severe and/or Exacerbation-Prone Asthma Network (PrecISE) is a five-year study sponsored by the National Heart, Lung, and Blood Institute (NHLBI). The study aims to identify more effective treatments for severe asthma which affects nearly 10% of people worldwide, and remains poorly controlled for many patients. The study is an innovative clinical trial that will support a personalized medicine approach to identifying therapies which are tailored to an individual’s disease and treatment history.